2 results
Approved WMOCompleted
Explore the efficacy, safety and tolerability of oral R129160, 60 mg o.d. in patients with chronic idiopathic urticaria
Approved WMORecruiting
Phase 2:Primary ObjectivesTo determine the recommended Phase3 dose of mitapivat by evaluating the effect of 2 dose levels of mitapivat versus placebo on:• Anemia in subjects with sickle cell disease (SCD)• SafetySecondary ObjectivesTo evaluate the…